BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 9443740)

  • 1. Tumor pretargeting for radioimmunodetection and radioimmunotherapy.
    Zhu H; Jain RK; Baxter LT
    J Nucl Med; 1998 Jan; 39(1):65-76. PubMed ID: 9443740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies.
    Zhu H; Baxter LT; Jain RK
    J Nucl Med; 1997 May; 38(5):731-41. PubMed ID: 9170438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model.
    Sharkey RM; Karacay H; Griffiths GL; Behr TM; Blumenthal RD; Mattes MJ; Hansen HJ; Goldenberg DM
    Bioconjug Chem; 1997; 8(4):595-604. PubMed ID: 9258460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
    Sharkey RM; Karacay H; Richel H; McBride WJ; Rossi EA; Chang K; Yeldell D; Griffiths GL; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.
    Karacay H; Sharkey RM; McBride WJ; Griffiths GL; Qu Z; Chang K; Hansen HJ; Goldenberg DM
    Bioconjug Chem; 2002; 13(5):1054-70. PubMed ID: 12236788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
    Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
    J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
    Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
    Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
    Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
    J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
    Moosmayer D; Berndorff D; Chang CH; Sharkey RM; Rother A; Borkowski S; Rossi EA; McBride WJ; Cardillo TM; Goldenberg DM; Dinkelborg LM
    Clin Cancer Res; 2006 Sep; 12(18):5587-95. PubMed ID: 17000696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.
    Goldenberg DM; Sharkey RM; Paganelli G; Barbet J; Chatal JF
    J Clin Oncol; 2006 Feb; 24(5):823-34. PubMed ID: 16380412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
    Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
    Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretargeted radioimmunotherapy of cancer: progress step by step.
    Boerman OC; van Schaijk FG; Oyen WJ; Corstens FH
    J Nucl Med; 2003 Mar; 44(3):400-11. PubMed ID: 12621007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.
    Hosono M; Hosono MN; Kraeber-Bodéré F; Devys A; Thédrez P; Fiche M; Gautherot E; Barbet J; Chatal JF
    J Nucl Med; 1998 Sep; 39(9):1608-13. PubMed ID: 9744353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
    Kraeber-Bodéré F; Faivre-Chauvet A; Ferrer L; Vuillez JP; Brard PY; Rousseau C; Resche I; Devillers A; Laffont S; Bardiès M; Chang K; Sharkey RM; Goldenberg DM; Chatal JF; Barbet J
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3973S-81S. PubMed ID: 14506196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic comparison of direct antibody targeting with pretargeting protocols based on streptavidin-biotin binding.
    Sung C; van Osdol WW
    J Nucl Med; 1995 May; 36(5):867-76. PubMed ID: 7738665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.
    Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Begent RH
    Cancer Biother Radiopharm; 2001 Oct; 16(5):391-400. PubMed ID: 11776756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods.
    Sharkey RM; Karacay H; Cardillo TM; Chang CH; McBride WJ; Rossi EA; Horak ID; Goldenberg DM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7109s-7121s. PubMed ID: 16203810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
    van Schaijk FG; Oosterwijk E; Soede AC; Oyen WJ; McBride WJ; Griffiths GL; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A universal pretargeting system for cancer detection and therapy using bispecific antibody.
    Sharkey RM; McBride WJ; Karacay H; Chang K; Griffiths GL; Hansen HJ; Goldenberg DM
    Cancer Res; 2003 Jan; 63(2):354-63. PubMed ID: 12543788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical evaluation of a new murine monoclonal antibody (Mu-9) against colon-specific antigen-p for targeting gastrointestinal carcinomas.
    Sharkey RM; Goldenberg DM; Vagg R; Pawlyk D; Wong GY; Siegel JA; Murthy S; Levine GM; Izon D; Gascon P
    Cancer; 1994 Feb; 73(3 Suppl):864-77. PubMed ID: 8306272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.